Introduction
============

Despite advances in understanding the molecular biology of prostate and breast cancers, they are still the most frequently diagnosed cancers in men and women, in the United States. There is no completely effective preventative for either prostate or breast cancer. Advances in the chemoprevention of prostate cancer remain controversial ([@bib30]) and none are approved by the Food and Drug Administration (FDA). As a result, there were 220,800 new cases of prostate cancer reported with 27,540 deaths ([@bib239]) in men. Advances in chemoprevention have been made in breast cancer ([@bib135], [@bib138], [@bib139], [@bib60], [@bib63]), but the task of implementation is not trivial ([@bib148], [@bib192], [@bib243]). There were 231,840 new breast cancer cases reported in 2015, accounting for almost 29% of the total estimated female cancers ([@bib239]). Approximately, 40,290 deaths from breast cancer occurred in 2015 accounting for 14% of total deaths from cancers in women ([@bib239]). These figures present a major challenge in clinical research and for healthcare systems worldwide. Indeed, it is estimated that the incidence of breast cancer will increase by 50% from the level in 2011 for the combination of Indolent Lesion of Epithelial Origin (IDLE) and invasive disease by 2050 ([@bib10]). The increased survival of an aging population is the cause of the relentless rise in cancer. The goal of a cure remains. However, in practical terms, new affordable strategies are required for individuals affected by prostate or breast cancers to remain productive members of their families and society.

The sex steroid hormones i.e. androgens in men and estrogens in women play critical roles in the development and progression of prostate and breast cancers. Prostate cancer development relies on the androgen receptor (AR), whereas breast cancer development primarily relies on the estrogen receptor (ER). The majority of prostate and breast cancers are hormone dependent ([Fig. 1](#fig1){ref-type="fig"}). Antihormone therapies have had a profound impact in reducing the burden from breast cancer, worldwide ([@bib131], [@bib224], [@bib240]). Here, we will address whether the lessons learned in breast cancer can be applied to prostate cancer therapy. Whether treatment strategies are the same or not for both diseases, resistance to antihormone treatments occurs in both prostate and breast cancers. Figure 1A schematic representation of the androgen and estrogen deprivation therapy in prostate cancer and pre- and postmenopausal women with breast cancer. (A) The hypothalamic--pituitary--gonadal and adrenal axis in prostate cancer with their therapeutic targets. The hypothalamus produces gonadotropin-releasing hormone (GnRH), which stimulates the adenohypophysis of the pituitary to produce adrenocorticotropic hormone (ACTH). This in turn, stimulates the adrenal gland cortex to produce androgens: dehydroepiandrosterone sulfate (DHEA-S) predominately, DHEA and androstenedione (AD) into the circulation. These androgens (A), alongside testosterone (T) from the testes, are converted in the prostate to their potent form, dihydrotestosterone (DHT). Dihydrotestosterone stimulates the growth of prostate cancer cells and exerts a negative feedback loop onwards to the hypothalamus and pituitary. Both, GnRH agonists/antagonists suppress LH production and cause a subsequent decline in serum testosterone to castrate levels. However, GnRH agonists (with chronic use) lead to the downregulation of GnRH receptors, whereas, GnRH antagonists usually cause an immediate blockade to the receptor. At the adrenal level, abiraterone inhibits adrenal androgen *de novo* steroidogenesis. At the prostate level, androgen receptor (AR) inhibitors are used and they have different mechanisms of action. For example, enzalutamide competitively inhibits the AR binding to DHT, inhibits nuclear translocation, and DNA and cofactor binding. Whereas, Bicalutamide is a highly selective, competitive and silent antagonist to the AR, which was also found to accelerate AR degradation. (B) The hypothalamic--pituitary--gonadal axis in premenopausal women with breast cancer and their therapeutic targets. The hypothalamus produces gonadotropin-releasing hormone (GnRH), which stimulates the adenohypophysis of the pituitary to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This in turn, stimulates the granulosa cells in the ovarian follicles to produce estrogen. However, FSH in particular stimulates the granulosa cells to produce inhibin, which suppresses FSH in a feedback loop and activin, a peripherally produced hormone that stimulates GnRH cells. Estrogen stimulates the growth of breast cancer cells, and exerts a negative feedback loop onwards to the hypothalamus and pituitary. Ovarian suppression can be achieved with LHRH superagonists such as goserelin, which is an analogue of LHRH, and a GnRH or LHRH agonist. Goserelin initiates a flare of LH production and ultimately leads to receptor downregulation. Antiestrogens can be estrogen receptor (ER) competitive blockers such as the Selective ER Modulators (SERMs, i.e. tamoxifen), or pure antiestrogens or what is known as a Selective ER Downregulators (SERDs, i.e. fulvestrant). Third-generation aromatase inhibitors (i.e. anastrozole, letrozole, exemestane) selectively block the aromatase enzyme system at the breast cancer level and therefore suppress estrogen synthesis. (C) The hypothalamic--pituitary--gonadal axis in postmenopausal women with breast cancer and their therapeutic targets. The differences from premenopausal women is that the ovarian follicles are depleted, therefore there is no active production of estrogen and progesterone. This leads to a dramatic increase in GnRH, an increase in FSH serum level relatively to that of LH through the feedback loops. Ovarian suppression is not used as a treatment option.

Currently, resistance to antihormone therapies in prostate and breast cancers are categorized as acquired resistance and *de novo* (intrinsic) resistance. It is considered that *de novo* resistance has the same mechanisms as the acquired resistance ([@bib115], [@bib177]), for the exception that these mechanisms are in place before the antihormone therapy is applied. We will focus on acquired resistance. In this review, we summarize the development of treatment approaches, the antihormonal agents used for the control of both diseases and the current understanding of the evolution of resistance to antihormonal therapies. We bring together these two major sex steroid-related diseases to define similarities and differences and compare and contrast treatments based on acquired antihormone resistance. We discuss the similarities of the phenomenon of sex steroid-induced apoptosis in both types of cancers after acquisition of antihormone resistance and explore the possibility that this new knowledge will have clinical applications. An innovative treatment approach that delivers affordable healthcare will save lives globally.

Hormonal therapies for prostate and breast cancer
=================================================

A diagnosis of advanced prostate cancer or breast cancer was a death sentence before 1940s, with patients dying within 1--2 years after diagnosis. Today, these same patients will have an earlier diagnosis, better care, but will still die within 3 years of diagnosis of stage IV disease. The number of patients with advanced prostate cancer has declined in the past 70 years, as early detection and diagnosis with proper treatment and monitoring has increased the 5-year survival rate up to 80--90% ([@bib153]). The change in the approach to treatment started when Professor Charles Huggins reported the response of metastatic prostate cancer (MPC) to androgen deprivation therapy (ADT), using surgical castration or high-dose synthetic estrogen therapy ([@bib119]). Diethylstilbestrol (DES) became a standard of care. Huggins won the Noble Prize in 1966 for developing a logical treatment strategy for prostate cancer with the ADT. Since then, ADT has been used as the gold standard for the treatment of MPC.

Earlier, but parallel, advances were reported for the treatment of advanced breast cancer in women. The initial experiment of oophorectomy ([@bib21]) was proven to be effective in 30% of premenopausal breast cancer patients with metastatic breast cancer (MBC) ([@bib32]). This was followed by a number of surgical ablation strategies and additive hormonal therapies for MBC ([@bib152]).

In the mid-1940s, Alexander Haddow ([@bib111]) was the first to discover that high doses of synthetic estrogens, including DES, could be used to treat postmenopausal women with MBC with a 30% response rate. Haddow's ([@bib111]) clinical trial showed that only breast and prostate cancers were responsive, whereas all other types were not. Nevertheless, at that time, the mechanism of action was not understood ([@bib110]). However, one important clinical fact did emerge. High-dose estrogen was only effective as an antitumor agent in MBC if used 5 years or more after menopause. High-dose estrogen therapy became the gold standard for the treatment of women with MBC until the introduction of tamoxifen 30 years later ([@bib131]). The biologic mechanisms and therapeutic significance of estrogen therapy was, at that time, obscure. However, the development of models to discover mechanisms of what became the new biology of estrogen-induced apoptosis ([@bib133], [@bib136]) is now the central theme of this position paper.

The discovery of the AR in the late 1960s by three independent groups of Liao ([@bib9]), Bruchovsky ([@bib37]) and Mainwaring ([@bib169]), was an important breakthrough, as it triggered the search for androgen antagonists. Similar advances were made with the discovery of the ER in the early 1960s. Jensen first described the binding of radiolabeled estradiol in rat estrogen target tissues ([@bib123]), and three years, later in 1966 Toft and Gorski identified the actual ER protein ([@bib255]). Nevertheless, the therapeutic breakthrough of non-steroidal antiestrogens was focused on the modulation of fertility in rodents and women during the 1960s before the discovery of the ER ([@bib129], [@bib161]).

In the early 1970s, the first non-steroidal antiandrogen flutamide was discovered ([@bib182]) and was approved in 1989 by the FDA for the treatment of prostate cancer. This discovery was followed by other non-steroidal antiandrogens including nilutamide ([@bib212]) and bicalutamide ([@bib93]), which were compared to castration in MPC patients in randomized trials. Results showed that antiandrogen drugs were better tolerated than castration ([@bib49], [@bib236]). However, they are inferior therapies in regard to overall survival (OS) and progression-free survival (PFS) ([@bib49], [@bib236]).

In 1971, an advance in physiology was made when Schally discovered the structure of the hypothalamic hormone known as the luteinizing hormone (LH)-releasing hormone (LHRH; called the gonadotropin-releasing hormone GnRH) ([@bib230]). This led to an understanding of the sex steroid feedback control mechanisms orchestrated by the hypothalamo-pituitary axis ([Fig. 1](#fig1){ref-type="fig"}). Advanced prostate cancer patients who were treated with daily doses of the LHRH agonists had a 75% decrease in serum testosterone levels, a decrease or normalization of plasma acid phosphatase levels, and a significant decrease in cancer-associated bone pain ([@bib256]). In 1977, Schally received the Nobel Prize in Physiology and Medicine for discovering peptide hormone production in the brain. Many synthetic LHRH superagonists were subsequently developed for clinical use ([@bib229]), such as buserelin, goserelin, leuprolide and nafarelin. Additionally, many LHRH antagonists have been developed and tested for the treatment of men with advanced prostate cancer such as orgalutran, cetrorelix and abarelix ([@bib229]). An antagonist was considered to be necessary as the superagonists first stimulate gonadotropin release (which causes an androgen burst) before a desensitized and refractory state occurs. Estrogen has been used to treat prostate cancer by lowering gonadotropin levels and as a result androgen levels. Estrogen was evaluated successfully to block the stimulatory rise in gonadotropin caused by LHRH superagonists ([@bib3]).

Fernand Labrie ([@bib157]) was one of the pioneers who developed the idea of a complete androgen blockade using combination antiandrogen therapy with flutamide and LHRH agonists or surgical castration in patients with MPC increasing the PFS and OS. Crawford and colleagues ([@bib56]) demonstrated that the combination of flutamide and leuprolide resulted in a slightly longer PFS. As a result, many physicians in the United States shifted toward combined androgen blockade as initial therapy for advanced prostate cancer. The signaling pathways of the AR and mechanism of action of different antiandrogens is depicted in [Fig. 2](#fig2){ref-type="fig"}. Figure 2A schematic representation of the signal transduction pathways in ER-positive breast cancer cells and prostate cancer cells. (A) At the adrenal level, adrenal androgen *de novo* steroidogenesis occurs. Cholesterol is produced and converted to Pregnenolone with the aid of CYP11A1 enzyme. Pregnenolone is converted to dehydroepiandrosterone (DHEA) with the aid of CYP17A1. Finally, DHEA is converted to androstenedione (AD) with the aid of 3-β hydroxysteroid dehydrogenase enzyme. Then, AD is converted to testosterone via 17-β hydroxysteroid dehydrogenase. At the adipose tissue level, Both androstenedione and testosterone are converted with the aid of the aromatase enzyme system to estrone (predominant in postmenopausal women), and estradiol (predominant in premenopausal women), sequentially. Estrogen normally binds to the ER in the cytoplasm, the estrogen:ER complex translocates to the nucleus, gets phosphorylated, and binds to estrogen responsive elements (EREs) with the recruitment of coactivators. This creates a transcription complex (TC). This in turn, will initiate a cascade of protein synthesis and subsequent tumor proliferation through the activation of estrogen-sensitive genes. Whereas, SERMs:ER follows a similar pattern but recruits corepressors and inhibits protein synthesis; causing tumor regression. For SERDs, they bind to the ER causing an alien conformation. This leads to the destruction of the ER through the ubiquitin proteasome system; subsequently tumor regression. (B) At the adrenal level, adrenal androgen *de novo* steroidogenesis occurs. Cholesterol is produced and converted to Pregnenolone with the aid of CYP11A1 enzyme. Pregnenolone is converted to dehydroepiandrosterone with the aid of CYP17A1. Finally, DHEA is converted to DHEA-S with the aid of following enzymes: steryl-sulfatase (STS) and bile salt sulfotransferase. At the prostae level, DHEA-S in Leydig cells is converted back to DHEA via STS and then DHEA is converted to AD via enzyme 3β-HSD. Then, AD is converted to testosterone via enzyme AKR1C3, and finally to DHT via steroid 5α-reductase. Dihydrotestosterone normally binds to the AR in the cytoplasm, the DHT:ER complex translocates to the nucleus, gets phosphorylated, binds to androgen responsive elements (AREs) with the recruitment of coactivators. This creates a transcription complex (TC). This in turn, will initiate a cascade of protein synthesis and subsequent tumor proliferation through the activation of androgen-sensitive genes. Whereas, AR inhibitors:AR complex follows a similar pattern but recruits corepressors and inhibits protein synthesis; causing tumor regression. For SARDs, they bind to the AR causing the degradation of the receptor; subsequently tumor regression. Androgen receptor inhibitors vary in their mechanisms of action. For example, enzalutamide competitively inhibits the AR binding to DHT, inhibits nuclear translocation of AR, and DNA and cofactor binding. Whereas, bicalutamide is a highly selective, competitive and silent antagonist to the AR, which was also found to accelerate AR degradation. Abiraterone inhibits CYP17A1 and subsequently adrenal androgen *de novo* steroidogenesis. Dutasteride is a 5α-reductase inhibitor that blocks testosterone conversion into DHT.

In contrast, breast cancer treatment strategies followed a separate path with an early move from the treatment of MBC to adjuvant therapy following breast surgery. A key factor in the differences in the treatment strategies of prostate and breast cancer is the fact that the majority of breast cancer occurs after menopause when there is no hypothalamo--pituitary--ovarian communication to alter estrogen levels ([Fig. 1](#fig1){ref-type="fig"}). By contrast, a recognized menopause does not occur in men and, as a result, hormonal communication from the pituitary to the testicular target remains. Currently clinical strategies are being defined and refined to address breast cancer treatment in the premenopausal patients ([@bib1], [@bib221]).

The ER became the target for tamoxifen to treat breast cancer ([@bib146]) based on the National Cancer Institute consensus conference in Bethesda in 1974 on ERs in human breast cancer ([@bib175]). Treatment strategies in the 1970s for breast cancer proposed, long-term adjuvant antihormone therapy ([@bib128], [@bib135]) and the possibility of chemoprevention ([@bib127]). These treatment strategies were proposed before tamoxifen was approved for the treatment of MBC in the United States (December 29th, 1977).

The actual development of tamoxifen was not initially a major priority by the pharmaceutical industry, but dependent upon chance and the investment in young scientists ([@bib132], [@bib137]). Tamoxifen's withdrawal from clinical development and resurrection in the 1970s with a clear strategic plan for the development of the medicine was the key to success ([@bib132], [@bib135]). Tamoxifen became the standard for antihormonal therapy of ER+ MBC ([@bib92], [@bib131], [@bib132]). Five years of adjuvant treatment with tamoxifen improved clinical outcome compared to shorter adjuvant therapy ([@bib75]), and for more than a decade, 5 years of adjuvant tamoxifen ([@bib64]) (or aromatase inhibitors, AIs) was the standard of care for ER+ breast cancer. Tamoxifen was the first medicine, in a new group of medicines called the selective estrogen receptor modulators (SERMs) ([@bib174]). Ultimately, tamoxifen was the first antiestrogen to be approved by the FDA for the prevention of breast cancer in women ([@bib131]).

Another approach to treat breast cancer inhibits the aromatase enzyme system (CYP19) that catalyzes estrogen biosynthesis in postmenopausal women. This group of medicines is called the AIs, and these are currently used for the treatment of postmenopausal breast cancer patients. Aminoglutethimide was the first Al introduced, which has an efficacy in MBC patients ([@bib166]). Nevertheless, all the AIs used in the early 1970s were not specific for CYP19 and showed side effects with depression of adrenal function. Glucocorticoids needed to be used to compensate ([@bib227]). As a result, the first-generation AIs (aminoglutethimide and testololactone) were not suitable for adjuvant treatment ([@bib53]). The breakthrough occurred in the late 1970s with the discovery of the first specific inhibitor of the aromatase system, 4-hydroxy androstenedione ([@bib35], [@bib34]). This compound, known as formestane, demonstrated clinical efficacy in MBC ([@bib55], [@bib98], [@bib72]). Again, regrettably, the medicine was unsuitable for adjuvant trials of ER+ breast cancer, because it was an injectable. Soon after the development of the third generation of Als, (anastrozole, letrozole and exemestane) with lower toxicity, the Als became the adjuvant endocrine treatment of choice for the ER+ postmenopausal breast cancer patients ([@bib71]). The signaling pathways of the ER and mechanism of action of different antiandrogens are depicted in [Fig. 2](#fig2){ref-type="fig"}.

Current treatment strategies for prostate and breast cancers
============================================================

Various parameters, such as the tumor volume and the pathological grade, have been correlated with prostate cancer malignancy ([@bib31]). A strong correlation with an excellent prognosis was evident in prostate cancer presenting with a high percentage of AR-positive cells ([@bib16]). Prostate cancer that is AR negative is very rare; therefore, little attention has been given to this subtype. The aggressiveness of prostate cancer is based on the Gleason score, a system based on pathological grade. In prostate cancer, the lowest Gleason score sum found in a tumor biopsy is 6, which are low grade or well differentiated, less aggressive with slow growth and limited invasion and metastasis. The Gleason score sum of 8--10 are found in high-grade tumors, poorly differentiated, tending to be aggressive and quickly grow and spread. Gleason score sum of 7 is called intermediate grade and is found in moderately differentiated tumors.

Since prostate cancer is an indolent disease, the majority of men diagnosed will not be treated with any type of therapy. It was found that the majority of men with prostate cancer have lower prostate cancer-specific mortality rates and are more likely to die from age-related comorbidities ([@bib168], [@bib5]). However, if prostate cancer is graded as aggressive, then surgery and sometimes adjuvant radiotherapy are the therapies of choice. Radical prostatectomy alone in men with localized prostate cancer has a 7-year recurrence-free survival (RFS) of approximately 70% ([@bib149]) and the biochemical PFS of approximately 50% ([@bib29]). However, application of immediate adjuvant radiotherapy can further significantly increase clinical PFS ([@bib29]). If the disease has progressed in spite of primary therapies, has metastasized or is an advanced poor prognosis or/and high-grade tumor only then is hormonal therapy applied. Recurrent tumors that are nonmetastatic or for locally advanced tumors (tumors that have spread to nearby tissue or local lymph nodes) are sometimes treated with adjuvant hormonal therapy concomitantly with adjuvant radiotherapy. This can further increase PFS and OS, especially if applied at earlier time points ([@bib89], [@bib198], [@bib188], [@bib237]). Current treatments strategies for prostate cancer are summarized in [Fig. 3](#fig3){ref-type="fig"}. Figure 3A schematic representation of the treatment paradigms used clinically for breast and prostate cancers. (A) Early-stage prostate cancer (PC) is usually approached with active surveillance, local treatments such as: surgery and radiation therapy. Hormone therapy can be given for early-stage PC men if they were at high-risk, or if they cannot undergo surgery or radiation therapy. The newer treatments for early-stage PC are: Intensity-Modulated Radiation Therapy, Proton beam therapy, and Cryosurgery. If early-stage PC progresses to metastatic PC (MPC) or what is known as castration-sensitive PC (CSPC), it will be treated with androgen deprivation therapy (ADT) using GnRH agonists, or complete androgen blockade (CAB) using a GnRH agonist plus flutamide for example, or secondary hormone therapy (SHT) using abiraterone, or enzalutamide as examples. If CSPC progresses to castration-resistant PC (CRPC), it will be treated with ADT or SHT. About 60% of PC is diagnosed in men \>65, with 97% in men age \>=50. The median age at the time of diagnosis in the U.S. is about 66. (B) Early-stage BC can be treated with local treatments such as: surgery and radiotherapy or systemic treatments such as: hormone therapy. What sets early-stage BC treatment apart from prostate cancer is adjuvant therapy with tamoxifen or AIs for 5--10 years. If early-stage BC progresses to metastatic BC (MBC), one therapeutic option is fulvestrant. Breast cancer rates increase after age 40 and are highest in women \>70. The median age of diagnosis of BC for women in the U.S. is 62.

By contrast, breast cancer is a highly heterogeneous tumor with different malignant subtypes. Prat and Perou ([@bib206]) used gene expression profiling to classify breast cancer into subtypes based on the expression of the main receptors, ER, progesterone receptor (PR) the erythroblastosis oncogene (ErBB2, HER2/neu) and the AR: Luminal A (ER+, PR+, HER2− and low Ki-67, low grade), Luminal B (ER+, PR+, HER2+/−, high Ki-67 and high grade), human epidermal growth factor receptor 2 (ER−, PR− and HER2+), basal-like or triple-negative (TNBC) (ER−, PR− and HER2−), claudin-low (often TNBC with low expression of cell-to-cell contact proteins and E-cadherin, in particular, with infiltration of lymphocytes), Luminal ER−/AR+ (AR+ and respond to antihormonal therapy with antiandrogens ([@bib108])) and normal-like (ER+, PR+, HER−, low Ki-67 and normal like) breast cancers. Patients with ER+ early-stage breast cancer account for about 75% of breast cancer cases ([@bib113]). Though the primary therapies for early-stage breast cancers, regardless of their subtype are surgery and radiotherapy, long-term hormonal adjuvant therapy is used in most cases with ER+ breast cancers. The first FDA-approved antiestrogen tamoxifen is usually prescribed to premenopausal patients as they have a very low risk of developing endometrial cancer as a side effect from long-term tamoxifen treatment. The Early Breast Cancer Trialists' Collaborative Group in 2011 confirmed that five years of using tamoxifen as adjuvant treatment reduced the risk of death and reduced the 15-year recurrence risk by 40% ([@bib64]). The benefits of the 10-year extended therapy with tamoxifen were presented in two studies in 2013 with the 15-year follow-up of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial ([@bib65]) and the Adjuvant Tamoxifen To Offer More (aTTom) ([@bib102]) trial. The outcome of the ATLAS trial is that, ER-positive patients with extended tamoxifen therapy reduced the risk of breast cancer recurrence, mortality and reduced overall mortality ([@bib65]). The outcome of the aTTom trial was similar to the ATLAS trial confirming that, continuing tamoxifen treatment in ER-positive breast cancer patients for 10 years rather than just 5 years leads to further reductions in recurrence and subsequent decrease in mortality. The documentation for the clinical characteristics of high-risk patients eligible for extended tamoxifen therapy (\>5 years) have recently been published ([@bib194]).

For postmenopausal women with thromboembolic or no osteoporotic comorbidities, AIs are usually prescribed. Anastrozole was the first of the third-generation AIs used in a clinical trial called the Tamoxifen Alone or Combination (ATAC) trial ([@bib20]). Anastrozole has some advantages over tamoxifen as a first-line adjuvant treatment for early breast cancer in postmenopausal patients. Results for the combination treatment are the same as tamoxifen alone ([@bib20], [@bib62]). This was to be expected. A rule of pharmacology is that a partial agonist (tamoxifen) that binds to a receptor when combined with a therapy that removes the ligand from the body produces a response of the partial agonist alone. In 2010, a meta-analysis ([@bib71]) was performed and demonstrated the superiority of 2--3 years of tamoxifen followed by an AI for 2--3 years over 5 years of tamoxifen alone. Other clinical trials, referred to as the Breast International Group (BIG 1--98) ([@bib33]) and the adjuvant tamoxifen and exemestane in early breast cancer (TEAM-trial) ([@bib261]), were designed to address the question whether AIs would be superior to tamoxifen or not after 2--3 years of tamoxifen followed by switching to an AI for five years, showed no significant decrease in disease-free survival (DFS) or the RFS. A meta-analysis of individual data from postmenopausal patients with early-stage ER-positive breast cancers comparing 5 years of AIs against 5 years of tamoxifen or switching to an AI up to year 5 after 2--3 years of tamoxifen compared to 5 years of tamoxifen or an AI alone has shown that AIs have a significantly more favorable recurrence rates (RR) than tamoxifen by 30% ([@bib74]). AIs also caused more bone fractures, but fewer cases of endometrial cancers than tamoxifen (Early Breast Cancer Trialists' Collaborative Group 2015).

Currently, the period of adjuvant tamoxifen/AI treatment is extended up to 10 years based on the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG MA17), which showed the superiority of 5 years of tamoxifen followed by five years of letrozole compared to 5 years of tamoxifen alone ([@bib96]). Recently, Goss and colleagues found in the MA17 extension using an additional 5 years of AI for a 10 years total significantly increases the rates of DFS and decreases the incidence of contralateral breast cancer but the rate of OS was not increased ([@bib97]). It should be noted, however, that in the ATLAS trial ([@bib65]) and the combined analysis of ATLAS and aTTom trials mortality did not decrease significantly during extended adjuvant therapy but only a decade after extended therapy. As tamoxifen is a competitive inhibitor of estrogen action at the ER ([@bib129]), and is not cytotoxic, it is suggested that decreases in mortality occur by cell selection and subsequent estrogen-induced apoptosis from the woman's own estrogen ([@bib134], [@bib136]). Breast cancer remains the only cancer with an option of long-term adjuvant antihormone therapy proven to save lives. Current treatment strategies for breast cancer are summarized in [Fig. 3](#fig3){ref-type="fig"}.

The application of antihormone therapy is crucial in ER+ breast cancer as it is able to reduce the recurrence of breast cancer at least by half, and, unlike prostate cancer, which is an indolent disease, breast cancer will progress faster and recur without treatment. All prostate cancer patients and half of breast cancers develop acquired resistance to antiestrogen therapy.

Understanding acquired resistance to hormonal therapies in prostate cancer
==========================================================================

ADT is the primary therapy for prostate cancers that are classified as an aggressive type (high Gleasson score sum), advanced or locally advanced. The average duration of clinical responses to antiandrogen therapies in advanced prostate cancer is 12--18 months after which practically all patients evolve to castration-resistant prostate cancer (CRPC) tumor phenotype. CRPC is characterized by consistent elevation of prostate-specific antigen (PSA) despite ADT and/or metastases. It is estimated that 10--20% of all non-advanced prostate cancer patients will progress to CRPC after surgery or radiotherapy ([@bib153]).

Currently multiple examples exist for the molecular mechanisms of antihormone resistance in prostate cancer with an analogous classification for breast cancer. Each mechanism or their combinations may have clinical applications in individual cases. The mechanisms of acquired resistance to antihormone therapies for prostate cancer can be categorized based either on the dependence on the AR or dependence on the ligand ([Table 1](#tbl1){ref-type="table"}). Table 1Mechanisms of resistance to antihomrone treatments are similar in both prostate and breast cancer cancers.**CategoryMechanisms**Ligand-dependent, receptor-dependenthypersensitivity of the receptor to the ligand due to point mutationsincreased receptor expressionincreased transcriptional activity of the receptor due to changes in coregulators and corepressors levelsincreased levels of endogenous or circulating ligandLigand-independent, receptor-dependentgain-of-function mutations in the receptorcross-talk mechanisms with other growth factor pathwaysBypass pathway (ligand-independent, receptor-independent)deactivation of tumor suppressor pathwayshigh expression of anti-apoptotic and low expression of pro-apoptotic moleculesactivation of cell proliferation survival pathwaysHormone receptor negative, ligand-independentactivation of growth factor receptor pathwaysemployment of other types of hormone receptors[^1]

Ligand-dependent and receptor-dependent mechanisms of resistance
----------------------------------------------------------------

Mutations in the AR are found in almost 30% of metastatic CRPC (mCRPC) ([@bib181], [@bib263]). The majority of mutations in the AR are identified in the metastases, rather than in the primary tumors ([@bib170]) and may enable the AR to bind some antiandrogens, such as flutamide and bicalutamide, that act as AR agonists and fuel tumor cell growth ([@bib39], [@bib27],[@bib28]). We have performed molecular dynamics modeling to demonstrate the difference in the conformations of the ligand-binding domains (LBD) of the wild-type (wt) AR bound with an agonist (DHT) and antagonist bound with wtAR and a mutant AR found in CRPC ([@bib27]) ([Fig. 4](#fig4){ref-type="fig"}). The modeling results show that, when compared with the wtAR:DHT complex ([Fig. 4A](#fig4){ref-type="fig"}), the helix 12 of the mutantAR:bicalutamide complex closes over the LBD of the receptor, which provides agonist conformation of the AR and its subsequent activation ([Fig. 4C](#fig4){ref-type="fig"}). It should be noted that the precise mechanism of antiandrogen action at the LBD of the AR remains unclear ([@bib26], [@bib73], [@bib250]). Activating mutations at the ER can explain the phenomenon of antiandrogen withdrawal syndrome, when the termination of therapy with antiandrogens is followed by regression of tumors ([@bib112]). Figure 4Molecular modeling of the wild-type and mutant ER and AR bound with agonists and antagonists. (A) wtAR:DHT LBD complex (PDB ID: 3L3X); (B) the best docking pose of the wtAR:bicatulamide complex (PDB ID: 3RLJ), obtained via flexible docking (the experimental structure used for docking was selected based on the 3D similarity between bicatulamide and the available ligands co-crystalized with AR WT, thus the experimental structure 3RLJ was selected due high similarity between the native ligand, S-22 and bicatulamide). The major interactions are shown in dashed lines and colored as follows: hydrophobic interactions in lavender, pi-pi interactions in purple, water-mediated H-bonds are shown in blue, and classical H-bonds are depicted in green.; (C) T741L AR mutant:bicatulamide LDB complex (PDB ID: 1Z95), helix 12 is colored in green and the major interactions are shown in dashed lines and colored as follow: hydrophobic interactions in lavender, pi-pi interactions in purple, water-mediated H-bonds are shown in blue, and classical H-bonds are depicted in green; (D) wtER:E2 LBD complex (PDB ID: 1GWR); (E) wtER:endoxifen LBD complex; (F) Superposition of E2 D538G mutant with ERα D358G apo LBD structures (helix 12 is shown in red for apo conformation and pink in the E2 bound mutant structure). The major interactions are shown in dashed lines and colored as follow: hydrophobic interactions in lavender, pi-pi interactions in purple, water-mediated H-bonds are shown in blue, and classical H-bonds are depicted in green.

Besides various mutations of the AR that contribute to the endocrine resistance in CRPC, a new role of membrane-associated AR isoforms in CRPC is emerging. Membrane-bound ARs have been identified in LNCaP cells and in hormone-insensitive DU145 cells and are associated with rapid non-genomic hormone responses in cells ([@bib197], [@bib195],[@bib196]). However, very little is known about the significance of the membrane-bound ARs in CRPC, but recent report identifies an AR splice variant called the AR8 that is shown to be associated with castration resistance in prostate cancer ([@bib271]). Overexpression of the AR8 isoform increases the association of the receptor with the EGFR in CRPC cells and promotes cell proliferation and survival ([@bib271]).

The AR in CRPC cells can become hypersensitive to low doses of androgens. This hypersensitivity is associated with mutations in the AR itself, leading to an increased sensitivity of the receptor to low concentrations of circulating androgens ([@bib104]). Additionally, overexpression of the AR can be another AR-dependent mechanism that creates hypersensitivity. Indeed, it was shown that 30% of CRPC tumors overexpress the AR at high levels in the cells and 80% of patients show an elevated gene copy number ([@bib86], [@bib263]), which may be a result of selection of cell populations with high levels of the AR under androgen deprivation pressure ([@bib210]). An increase in the AR expression is associated with the amplification of the AR gene and in some cases attributed to polysomy of the X chromosome ([@bib219]). However, androgen action is not dependent upon the AR alone but is modulated by coregulators. The levels of expression of these coactivators, particularly SRC1 and SRC2, are higher in poorly differentiated prostate tumors or in recurrent prostate cancers and provide cells with higher AR activity in a low-dose androgen environment ([@bib91], [@bib103]). Additional AR-specific coactivators of note have been identified: ARA70 increases the AR activity and even facilitates the binding of estradiol to the AR ([@bib273]), FKBP51 stabilizes the AR with HSP90 heat-shock protein complex and facilitates the binding of androgens ([@bib184]), and TRIM24 increases AR transcriptional activity ([@bib106]).

Long-term antiandrogen therapy can affect the hypothalamo--pituitary axis as a negative feedback loop in men, leading to a compensatory increase of circulating androgens ([@bib210]). This, by itself, can activate the AR by the law of mass action, but testosterone is not the physiologic ligand as it is required to be converted to dihydroxytestosterone (DHT) in the prostate cancer cell. Increased 5α-reductase enzyme activity contributes to the increase of endogenous androgens in the tumor. This results in the selection of CRPC cells able to convert androgen to endogenous DHT to produce a growth advantage ([@bib181], [@bib254], [@bib46]). A polymorphism in the 5α-reductase gene is noted in men of African-American descent, which is responsible for higher enzymatic activity in prostate cancer cells, as well as in prostate cancer cases with bad prognosis ([@bib222]). In fact, the intratumoral levels of androgens can be as high as 40% above the baseline levels before ADT ([@bib185]). Recently another polymorphism in HSD3B1, which encodes 3β-hydroxysteroid-dehydrogenase-1 has been identified in a retrospective study of CRPC as a factor that correlates with an increased DHT synthesis ([@bib114]).

Ligand-independent and receptor-dependent mechanisms of resistance
------------------------------------------------------------------

Most mutations are point gain-of-function mutations and are mostly located in the LBD of the AR and allow other sex steroids, such as glucocorticoids to bind to the AR and activate it ([@bib277]). Resistance to abiraterone was demonstrated in some mCRPC tumors with mutated AR ([@bib43], [@bib47]). Additionally, alternative AR mRNA splice variants occur that generate constitutively active AR proteins ([@bib69], [@bib265], [@bib38]).

Increased expression of certain growth factors are associated with increased activity of the AR in mCRPC as well. The subversion of the AR transcriptional activity via growth factor receptor-mediated growth is called the cross-talk. Epidermal growth factor (EGF), keraticocyte growth factor (KGF) and insulin-like growth factor 1 (IGF-I) can activate the AR and can be reversed by antiandrogens ([@bib58]). Tyrosine kinase receptors, such as HER2, which is highly expressed in CRPC cells, can also activate the AR via phosphorylation, through activation of the MAPK and the Akt pathways ([@bib165]). The growth factor IL-6 is responsible for the progression of CRPC. This occurs by increasing AR activity by 50% more than observed with DHT alone ([@bib57]). Resistance to growth inhibition occurs through the MAPK and STAT3 pathways, induces autophosphorylation of HER2 to activate the AR-mediated cascade independent of the ligand ([@bib48], [@bib57]). High expression levels of the AR mRNA are maintained by NF-κB in CRPC cells, which sustains high AR protein levels ([@bib276]).

Bypass pathway
--------------

One of the mechanisms of resistance involves recruitment of cellular survival pathways in CRPC, but the tumors still express the AR. However, the tumor cells do not require active AR to proliferate and survive. This mechanism is called the bypass pathway. Over expression of the antiapoptotic genes like Bcl-2, Bcl-xL and NF-kB ([@bib94]) are characteristic of the bypass pathway. Activation of other cell survival signaling pathways like PI3K/Akt has also been examined and linked with CRPC progression ([@bib251]). Mutations in tumor suppressor genes, like PTEN, also play a role in hormone resistance and allow the cells to rapidly progress though the cell cycles ([@bib164], [@bib180], [@bib76]). Mutated BRCA1 and BRCA2 tumor suppressor genes that are strongly associated with breast cancer incidence and progression have also been shown to be present in CRPC cells and associated with progression of prostate cancer cells to a CRPC phenotype ([@bib220], [@bib156], [@bib160], [@bib217]). Several other proteins have been identified that are associated with AR bypassing and progression and survival of therapy-resistant CRPC, such as TWIST1, DKK3 and VAV3 ([@bib171]).

Recently, other possible contributing factors to the progression of CRPC disease were identified. Some estrogens are synthesized in males and the ERα is expressed in CRPC cells. The activation of the ERα stimulates proliferation and migration of the tumor cells ([@bib15], [@bib178]). The estrogen-related receptor (ERR) induces bone metastases and activation of VEGF-A, WNT5A and TGFβ1 in mCRPC cells ([@bib90]). The glucocorticoid (GR) and the mineralocorticoid receptors (MR) have been associated with the progression of CRPC and being able to substitute and bypass the blocked AR ([@bib13]). It appears that the GR and the AR have an array of common response genes due to homologous DNA-binding domains of the receptors ([@bib223], [@bib105]).

Ligand-independent mechanisms of resistance with the loss of the AR
-------------------------------------------------------------------

Antiandrogen resistance in prostate cancer can also be ligand independent and AR negative. Loss of expression of the AR in CRPC has been recorded in 30% of cases ([@bib249]) due to hypermethylation of the AR gene ([@bib122]). This epigenetic deregulation of the AR expression is much more common for the CRPC compared to only 10% of *de novo* hormone-resistant prostate cancers ([@bib249]). Selected cells, with loss of the AR expression after antihormonal therapy, have adapted and 'hijacked' pathways enabling them to grow using other growth stimulatory pathways and even employ other hormone receptor pathways.

Understanding acquired resistance to hormonal therapies in breast cancer
========================================================================

The mechanisms of antihormone resistance in breast cancer cells are very similar to the mechanisms in CRPC ([Table 1](#tbl1){ref-type="table"}) ([@bib210], [@bib215]).

Ligand-dependent and receptor-dependent mechanisms of resistance
----------------------------------------------------------------

The hypersensitivity of breast cancer cells to low doses of estrogens during estrogen ablation therapy has been associated with increased levels of ER expression. For instance, the ER protein levels were shown to be higher in long-term estrogen-deprived (LTED) MCF-7 cells by as high as 10-fold ([@bib150], [@bib266]). This can also happen in estrogen depletion with tamoxifen treatment ([@bib25]). One of the possible pathways of such hypersensitivity to estrogens was explained by a non-genomic activity of the ER, when it phosphorylates Shc, which in turn binds to signaling proteins Grb-2 and Son of Sevenless (SoS). As a result, this activates MAPK/ERK via Ras and Raf and promotes the phosphorylation of the ER at the AF-1 motif and activation of the receptor ([@bib226]). The increased transcriptional activity of the ER can also be upregulated by overexpressed coactivators. Estrogen receptor coactivator SRC3 is the most important for breast cancer as its expression is restricted to only a few tissues, including the breast ([@bib247]). Clinical studies ([@bib189], [@bib6]) noted that high levels of SRC3 coactivator were associated with worse outcomes in tamoxifen-treated breast cancer patients. Low corepressor expression has been described in tamoxifen-resistant tumors and has been reviewed elsewhere ([@bib158]). Asides from the levels of the ER protein and its activity modulating cofactors, high levels of circulating and intratumoral hormones can also provide antihormone resistance. As tamoxifen binds and blocks the ER in breast tumor cells, it can also bind to the ER in pituitary gland and hypothalamus and disrupt the negative feedback loop. Tamoxifen induced an elevation of the circulating levels of estrogens secreted from the ovaries by increasing gonadotropin-releasing hormone production. This mechanism has been used to explain the elevated levels of estrogens in tamoxifen-treated premenopausal patients ([@bib211], [@bib145]). The aromatase enzyme, that converts androgens to estrogens, can also be elevated in estrogen-deprived cells adaptively *in vitro* ([@bib275]) and can be stimulated through stromal cells that express prostaglandin E2, IL-6, 11 and tumor necrosis factor α (TNFα) ([@bib233]). Indeed, it was shown that breast tumor tissues have higher levels of aromatase expression than peritumoral tissues ([@bib40]).

In recent years, antihormone resistance was also linked to the expression of membrane-associated ERs. The first membrane-associated ER that was identified was GPR30. It was demonstrated that the translocation of GPR30 to the cell surface significantly increased after estrogen treatment in tamoxifen-resistant breast cancer cells and its activity was mediated through the EGFR ([@bib120], [@bib179]) and it is able to attenuate the inhibition of MAPK as well ([@bib179]). It was also shown that GPR30 is able to upregulate aromatase expression in tamoxifen-resistant breast cancer cells, which can be linked to the sensitivity to AIs in breast cancer patients with acquired or *de novo* resistance to tamoxifen ([@bib45]). Another novel variant of ER that was recently identified is the membrane-bound ER-α36 that is associated with tamoxifen resistance *in vitro* ([@bib264], [@bib107]). However, the clinical roles these findings are yet to be determined.

Ligand-independent and receptor-dependent mechanisms of resistance
------------------------------------------------------------------

Just like in the case with CRPC, one of the ligand-independent receptor-positive mechanisms of resistance in breast cancer could the activating mutations of the ER. Mutations of the ESR1 gene, that encodes the ER, have been identified in the LBD of the receptor in 14--54% of clinical samples from metastatic breast cancer patients and have also been linked to antihormone resistance ([@bib218], [@bib124]). These mutations are found most often in the metastases rather than in the primary tumors. Most mutations occur in positions Y537 and D538 and are described as gain-of-function mutations, which lead to constitutive ligand-independent activation of the ER ([@bib218], [@bib258]). Amino acid residues 537 and 538 are positioned in the AF-2 motif of the ER LBD so that mutations of these residues can induce a ligand-independent agonistic conformation of H12, closing the unoccupied LBD by interacting with residue at position 351 ([@bib142]). The ligand-free ER then recruits coactivators and activates the ER, even with the binding of tamoxifen (ligand dependent) ([@bib183], [@bib142], [@bib83]). We have also performed molecular dynamics modeling to demonstrate the conformational perturbation of the ER LBD with D538 mutation ([@bib83]) ([Fig. 4](#fig4){ref-type="fig"}).

ER-positive resistance in breast cancer is also attributed to the activation of growth factor pathways, such as HER2, IGF-1R and FGFR and stress-related kinases, such as AKT, JNK, MAPKs, c-SRC and others, that regulate posttranslational modifications of the ER and its coactivators that increase the receptor activity ([@bib232], [@bib238], [@bib225], [@bib252]). There is clinical evidence that proves that differential expression of various growth factor receptors in tamoxifen-resistant tumors are associated with resistance to tamoxifen and can play a role of a predictive clinical marker for therapy efficacy ([@bib41], [@bib257]). Interestingly, these mechanisms can increase the membrane-associated ER activity with 17β-estradiol (E~2~) or even tamoxifen, also contributing to resistance in breast cancer. Increased levels of NF-κB and AP-1 can tether more ER to certain gene promoters and promote hormonal resistance ([@bib278]).

Bypass pathway
--------------

Ligand and ER-independent mechanism depends upon MYC, Cyclin E1 and D1, p21 and p27 can promote progression through cell cycle despite tamoxifen therapy ([@bib245], [@bib42], [@bib201], [@bib50]). Antiapoptotic molecules, such as Bcl-xL, can be overexpressed to inhibit pro-apoptotic molecules and promote survival ([@bib214]).

Evolution of acquired resistance in prostate and breast cancers
===============================================================

Antihormonal therapy is standard for the treatment of recurrent and metastatic prostate cancer, however, up to 90% of these patients will ultimately fail and develop CRPC disease within 12--33 months after ADT. To understand this process of acquired resistance, numerous studies *in vitro* and *in vivo* were performed to simulate long-term ADT in prostate cancer cells to decipher the evolving mechanisms of acquired resistance ([@bib155], [@bib260], [@bib126]) ([Fig. 5](#fig5){ref-type="fig"}). The studies to mimic long-term antiandrogen therapy in prostate cancer were performed using LNCaP cells, a popular AR-positive human cell line. Initial studies used various durations of steroid deprivation, with culture media containing charcoal-treated serum ([@bib155]). Continuous passaging of cells in androgen-deprived conditions led to the selection of clones hypersensitive to androgens. However, longer androgen starvation (2 years) of these clones let to the isolation of cells that grow independently from androgen, with an unanticipated vulnerability ([@bib155]). Low doses of androgen reduced the number of viable cells after 6 days of treatment ([@bib155]). The authors ([@bib155]) also noted a high level of AR protein and mRNA in these resistant cells compared to wild-type LNCaP cells. Expression of PSA protein and mRNA increased when treated with an androgen. Experiments *in vivo* using the same cells showed that the wild-type LNCaP tumors grew well in mice with androgen treatment; however, the derived resistant cell line grew only in castrated mice and treatment with DHT caused regression of the tumors ([@bib260]). The authors ([@bib260]) used further androgen deprivation of resistant cells in their experiments *in vitro* to derive a cell line that grew in androgen-deprived conditions as well as the wild-type cell line under testosterone stimulation. Interestingly, these resistant tumors were stimulated to grow with E~2~ and medroxyprogesterone acetate (MPA) and 5α-reductase inhibitor finasteride was able to partially reverse the tumoricidal actions of testosterone ([@bib260]). Figure 5A schematic representation of the parallel cellular evolution of acquired hormone resistance to hormone deprivation in prostate and breast cancer cell models *in vitro*. (A) LNCaP cell line is an androgen-sensitive human prostate adenocarcinoma cell line. When LNCaP cells are cultured in an androgen depleted environment for 8--11 months *in vitro*, they become hypersensitive to androgen; and subsequently proliferate. With extended androgen depletion of 16--20 months, selection pressure occurs and LNCaP cells become vulnerable to androgens with death through apoptosis. Cells then exhibit the characteristic morphology of apoptosis with apoptotic membrane blebbing, followed by formation of membrane protrusions (apoptopodia, microtubule spikes, and beaded apoptopodia, beads-on-a-string appearance), ending with cellular fragmentation into apoptotic bodies. (B) MCF-7 cell line is an estrogen-sensitive human breast adenocarcinoma cell line. When MCF-7 cells are cultured in estrogen depleted environment for 6--12 months *in vitro*, they become hypersensitive to estrogen; and subsequently proliferate. With extended estrogen depletion of 12--18 months, selection pressure occurs and MCF-7 cells are now vulnerable to estrogens with death through apoptosis. Cells then exhibit the characteristic morphology of apoptosis.

Another group has performed similar *in vitro* and *in vivo* studies with long-term androgen-deprived LNCaP cells ([@bib126]). Wild-type LNCaP cells were passaged in culture medium supplemented with charcoal-treated serum for 1 year ([@bib126]). The resulting cell line grew independently from androgen, however, treatment with various androgens, and even E~2~ resulted in retarded cell growth due to apoptosis ([@bib126]). Experiments *in vivo* showed that androgen induced apoptosis and tumor regression with this model ([@bib126]).

Liang and coworkers ([@bib52]) used variants of LNCaP prostate cancer cell lines to demonstrate that antiandrogen-resistant LNCaP cell lines with an AR-rich phenotype have a G1 cell cycle blockade in the presence of androgens by regulating cMyc, Skp2 and p27^kip^ via the AR. Additionally, they found that higher dosages of testosterone lead to more growth inhibition of relapsed tumors suggesting that the manipulation of androgen/AR signaling pathway may be a potential therapeutic target in AR-positive metastatic prostate cancer. Kawata and coworkers ([@bib151]) reported that prolonged treatment of a bicalutamide-resistant subline (LNCaP-BC2) with bicalutamide induces AR overexpression and androgen hypersensitivity to low levels of androgen. The authors identified the phosphorylated AR (pAR^210^) overexpression and a possible mechanism for androgen hypersensitivity. However, after long-term androgen deprivation, LNCaP prostate cancer cells evolve to be a cell population vulnerable to androgen-induced apoptosis ([@bib51]). Nevertheless, continuous treatment with androgens eventually selects for cells that will be resistant to the apoptotic actions of androgens and grow. The authors speculated that it would be possible to use intermittent androgen deprivation (IAD) to slow the progression of resistance and use androgen therapy during the relapse after the ADT cycle to further control the tumor progression ([@bib51]).

Clinically, there is evidence to support androgen-induced apoptosis in CRPC. Bruchovsky and coworkers ([@bib4], [@bib36]) used IAD to demonstrate that androgen action would inhibit growth of antiandrogen-resistant prostate cancer. There is evidence that IAD is able to prolong progression of resistant disease, and testosterone restoration between ablation therapy cycles can induce tumor regression in the laboratory *in vivo* ([@bib228]) and in the clinic ([@bib202], [@bib173]). In a recent viewpoint by Klotz and Higano ([@bib154]), IAD was described as a viable alternative to the continuous androgen deprivation (CAD) in men with no underlying cardiovascular diseases. The IAD strategy was preferable with improved quality of life, cheaper health care costs, despite no observed advantage over CAD in terms of OS. Recently, Schweizer and coworkers ([@bib235]) found a 50% response rate to androgen therapy when monitoring either PSA levels or radiologically identified CRPC disease.

Similar advances were made in studies of the antiestrogen resistance in breast cancer, and the evolution of breast cancer cells in the estrogen-free environment ([Fig. 5](#fig5){ref-type="fig"}). The evolution of MCF-7 breast cancer cells in estrogen deprivation conditions is similar to the evolution of LNCaP cells in response to androgen deprivation ([@bib144]).

Tamoxifen is a competitive inhibitor of estrogen action ([@bib129]) and long-term adjuvant tamoxifen therapy was predicted to be essential to suppress breast tumor cell growth ([@bib135]). Early studies using MCF-7 breast cancer cell line transplanted into oophorectomized athymic mice demonstrated that although tumors eventually developed despite tamoxifen therapy ([@bib190]), the tumors, in fact, grew because of tamoxifen therapy ([@bib100], [@bib99],[@bib101]). Tamoxifen-stimulated tumors were growth stimulated by either tamoxifen or physiologic estradiol. As a result, no estrogen treatment or treatment with a pure antiestrogen ([@bib99],[@bib101]) prevented tumor growth. Discovery of this biology of early acquired resistance to tamoxifen preceded the clinical finding that either an AI or the pure antiestrogen fulvestrant were appropriate second-line therapies after tamoxifen failure in MBC ([@bib118], [@bib191]). This unique form of acquired resistance has clinical relevance in SERM pharmacology with a withdrawal response in MBC to SERMs tamoxifen and raloxifene ([@bib117], [@bib70], [@bib159]). The recent development ([@bib78],[@bib79],[@bib80]) of an *in vitro* model of acquired resistance to SERMs has provided important insight into how either tamoxifen (SERMs) or estrogen can stimulate tumor cell growth. Estrogen-stimulated growth in early acquired resistance to tamoxifen *in vivo* is via a genomic pathway, but with estrogen action at genomic sites blocked by tamoxifen. By contrast, tamoxifen stimulates tumor cell growth non-genomically by enhancing the IGFR1β pathway.

It is important to reemphasize that high-dose synthetic estrogen therapy was the first chemical therapy to treat any cancer ([@bib111]). However, Haddow ([@bib110]) noted that high-dose synthetic estrogen therapy was only effective at producing a 30% response rate in MBC 5 years following menopause. If estrogen was administered therapeutically nearer to the menopause then MCB grew. The reasons for this clinical observation were unknown and mechanisms were not deciphered during the 1950s--1970s, when high-dose estrogen was the standard of care for postmenopausal MBC. In the 1970s, tamoxifen, a non-steroidal antiestrogen ([@bib131]), became the standard of care for all stages of breast cancer until the introduction of AIs in the late 1990s. There was no interest in understanding how high-dose estrogen therapy killed breast cancer cells despite the fact that high-dose DES produced a survival advantage over tamoxifen in a small trial in MBC ([@bib121], [@bib199]).

It is therefore ironic that the study of acquired resistance to tamoxifen treatment in breast cancer should expose a vulnerability of antihormone-resistant breast cancer i.e.: estrogen-induced apoptosis ([@bib268], [@bib272]). Most importantly, the MCF-7 breast tumors developed acquired resistance to tamoxifen by cell selection over a 5-year period. Within two years, acquired resistance is evidenced by tamoxifen-stimulated growth and estrogen-stimulated growth; the growth stimuli are interchangeable. However, between 3 and 5 years of tamoxifen exposure, tamoxifen stimulates tumor growth but physiologic estrogen causes complete regression of small (\<0.3 cm) tumors. The MCF-7 tumors rapidly regressed in response to E~2~. It was proposed ([@bib272]) that estrogen treatment of recurrent breast cancer following the failure of long-term tamoxifen treatment, will result in a tumor regression and breast cancer cells will regain their responsiveness to estrogen for growth. Tamoxifen causes a decrease in mortality and prevents disease recurrence after 5 years of stopping the therapy, i.e., does not cause a rebound effect anticipated for a competitive inhibitor of estrogen action. The reason suggested is that a woman's own estrogen causes estrogen-induced apoptosis in populations of vulnerable micrometastases that has long-term acquired resistance ([@bib272]). This hypothesis in now supported by considerable clinical evidence reviewed elsewhere ([@bib134], [@bib136]).

Song and coworkers ([@bib244]) reported that long-term estrogen deprivation leads to estrogen-induced apoptosis in LTED breast cancer cell population *in vitro*. Estrogen deprivation for a short time causes an elevation in the ER protein levels ([@bib150], [@bib266]). After 8--11 months of estrogen deprivation, MCF-7 cells acquire adaptive hypersensitivity to estrogen ([@bib172]), which is similar to LNCaP cells and hypersensitivity to androgen ([@bib86]). This may explain the early mechanism of AI resistance in breast cancer. Various cell models were developed over the years to study long-term estrogen deprivation in estrogen-free environment and using dilution cloning selection ([@bib125], [@bib204], [@bib244], [@bib163]). Two breast cancer cell lines were selected after long-term estrogen deprivation (2 years). MCF-7:5C and MCF-7:2A cell lines were at first characterized as ER positive and non-responsive to estrogens or antiestrogens ([@bib125], [@bib204]); however, optimization of culture conditions dramatically altered these characteristics ([@bib163]). The MCF-7:5C cells were shown to undergo low-concentration estrogen-induced apoptosis within a week of treatment in a concentration-dependent manner ([@bib163]), and the intrinsic mechanism of estrogen-induced apoptosis was described ([@bib162], [@bib82], [@bib81]). The MCF-7:2A cells undergo slow apoptotic alterations that occur within two weeks of treatment with estrogen. Both of these cell lines were used to investigate genome-wide alterations in estrogen-regulated gene expression profile involved in apoptosis ([@bib12]).

Current therapies for hormone-resistant prostate and breast cancers
===================================================================

Resistance to antihormonal therapy occurs in prostate and breast cancers, as new cell populations are selected after long-term sex steroid deprivation. These cells are characterized by sex hormone-independent growth.

It is believed that the AR in CRPC is still functional and can be abrogated to stop disease progression. Cytotoxic chemotherapy was routinely utilized to treat aggressive disease in the absence of targeted alternatives for CRPC prostate cancer. De Bono and coworkers ([@bib67]) compared cabazitaxel with the topoisomerase type II inhibitor mitoxantrone in mCRPC patients previously treated with docetaxel. Mortality was significantly decreased in the cabazitaxel group ([@bib67]). Smith and coworkers ([@bib241]) evaluated cabozantinib (XL184), which is an orally bioavailable tyrosine kinase inhibitor that acts against MET and vascular endothelial growth factor receptor 2 (VEGFR2), in CRPC patients. They concluded that cabozantinib has clinical efficacy in CRPC improving PFS with a decrease of soft tissue lesions, resolution of bone scans, decline of bone turnover markers, pain and use of narcotic painkillers. However, the major strategic advance for the treatment of CRPC is the realization that the AR is still functional in CRPC and, like in breast cancer, remains a potential target.

New antihormonal agents are improving the prognosis of CRPC. Abiraterone acetate ([@bib17]) is an inhibitor of cytochrome P450 (CYP17) ([Fig. 1](#fig1){ref-type="fig"}), which plays an essential role in *de novo* intratumoral androgen production from cholesterol in CRPC tumors ([@bib167]). This therapeutic approach to treat prostate cancer is analogous to the use of adjuvant therapy with AIs in postmenopausal breast cancer patients ([Fig. 3](#fig3){ref-type="fig"}). De Bono and coworkers ([@bib66]) evaluated abiraterone acetate in patients with mCRPC who have received chemotherapy and demonstrated that the inhibition of androgen biosynthesis by abiraterone prolonged the OS. Other approaches target the AR with new antiandrogens.

Scher and coworkers ([@bib231]) evaluated the antitumor activity and safety of enzalutamide, which blocks AR activity in men with CRPC ([Fig. 2](#fig2){ref-type="fig"}). Increasing doses of enzalutamide reduced serum PSA and stabilized bone disease in 56% of patients ([@bib231]). Recently, Penson and coworkers ([@bib200]) compared the efficacy of enzalutamide and bicalutamide in CRPC. Enzalutamide decreased the mortality of patients by 76% with a median PFS of 19.4 months compared to bicalutamide with a median PFS of 5.7 months. There was a significant increase in PFS with enzalutamide in the proportion of patients with a ≥50% PSA response, time to PSA progression and radiographic PFS in metastatic patients. Advantages of enzalutamide were observed in both metastatic and nonmetastatic subgroups. However, evidence is emerging on acquired resistance to abiraterone and enzalutamide ([@bib14], [@bib38], [@bib109]).

Several new antiandrogens are in early clinical development. The antiandrogen ARN-509 developed by Janssen Research & Development is an example of a potent competitive pure antiandrogen that has been evaluated in phase I/II trials in CRPC patients. In phase I trial, ARN-509 was well tolerated with fatigue being the most reported side effect ([@bib209]). In the phase II study, ARN-509 demonstrated an 80--90% efficacy in patients with naïve CRPC in both metastatic and nonmetastatic settings. There was a 29% response rate in mCRPC patients previously treated with abiraterone, reducing the PSA levels by more than 50% ([@bib208]). The novel small peptide EPI-001 targets the N-terminal domain of the AR containing the activating function-1 region (AF-1). This interrupts the AR's interaction with other proteins and androgen response elements in the androgen-responsive genes promoters. As a result, transcriptional activity is disrupted ([@bib7]). This peptide has not entered clinical trial, but showed promising results in the CRPC xenograft models ([@bib7]). A novel selective AR downregulating drug (SARD) AZD3514 had limited tolerability in CRPC patients in a phase I trial with modest antitumor activity; however, it did show activity in 17--25% of patients reducing PSA by more than 50% ([@bib187]). The authors concluded that developing SARDs in the future for treatment of CRPC may hold merit ([@bib187]).

Despite the use of long-term antiestrogen adjuvant therapy for breast cancer, approximately 50% of patients have disease recurrence. The question we must ultimately address is how we improve response rates? Though tamoxifen was approved initially for treatment of MBC in both pre- and postmenopausal women, AIs became the first-line therapy for postmenopausal breast cancer patients who did not have any prior hormonal therapy or have recurred within 12 months after previous adjuvant AI therapy. However, if the tumors recur in less than 12 months after hormonal therapy with an AI, then tamoxifen is recommended or a pure antiestrogen fulvestrant as second-line therapies. Recently, Robertson and an international team of colleagues ([@bib216]) in a phase III clinical trial have demonstrated superiority of fulvestrant over anastrazole as first-line therapy in postmenopausal patients with metastatic of locally advanced breast cancer. For premenopausal women, tamoxifen can be prescribed as first-line adjuvant hormonal therapy and AIs or fulvestrant can be used as second- and third-line therapies in case of cancer recurrence, but only with ovarian function suppression ([@bib1]). Antihormone resistance eventually occurs after exhaustive antihormone therapy fails. However, depending on the size and location of the metastasis cytotoxic chemotherapy is more likely to be used after a failed AI therapy rather than second or third-line antihormone agents.

New strategies for the treatment of hormone-refractory breast cancer are evolving based on inhibition of aberrant pathways. Abnormalities in the CDK4/6 and the mTOR pathways play a crucial role in the pathogenesis of breast cancer. These pathways are therapeutic targets for the treatment of naïve MBC or antihormone-resistant breast cancer. In phase I/II clinical studies ([@bib234]), palbociclib, which is a specific CDK4/6 inhibitor ([@bib186]), demonstrated an excellent bioavailability, mild to moderate adverse effects, and a well-tolerated toxicity. In phase III clinical study called PALbociclib Ongoing trials in the Management of breast cAncer-3 (PALOMA-3) ([@bib259]) the combination of palbociclib with endocrine therapy significantly improves PFS. All these data resulted in palbociclib receiving an FDA approval in 2015 as a first-line treatment for advanced postmenopausal ER-positive/HER2-negative breast cancer in combination with letrozole.

Numeral studies with mTOR inhibitors (i.e. everolimus, temsirolimus, deforolimus) show promise in the ER-positive and/or HER2-positive breast cancer ([@bib84], [@bib262], [@bib19]). The combination of everolimus with either an AI ([@bib23], [@bib87]) or fulvestrant ([@bib22], [@bib248], [@bib207]) demonstrated clinical efficacy. The Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) ([@bib18]), combined everolimus and exemestane for women with advanced ER-positive/HER2-negative breast cancer who previously failed AI therapy. In BOLERO-2, everolimus improved PFS in trastuzumab-resistant patients. Interestingly, in an early study with an mTOR inhibitor ([@bib68]) rapamycin ester (CCI-779) treatment restored tamoxifen response in tamoxifen-resistant breast carcinoma ([@bib274]).

Regrettably, combination therapies with CDK4/6 inhibitors or mTOR inhibitors with an antihormonal therapy do not result in lives saved, although life extension is a positive benefit. The question now becomes: how can adjuvant endocrine therapy be advanced based on what we now know from current clinical trials? There is a linear progression from therapeutic success in MBC to trials of adjuvant therapy, but we suggest this may not be that simple with CDK4/6 inhibitors and mTOR inhibitors.

The high monthly cost for both CDK4/6 inhibitors and mTOR inhibitors ([@bib44]), and the toxicity profile of grade 3/4 side effects with palbociclib ([@bib87]) (i.e. neutropenia, leukopenia, and lymphopenia), and grade 1/2 side effects with everolimus ([@bib18]) (i.e. fatigue, stomatitis, anorexia, diarrhea, noninfectious pneumonitis, metabolic disorders with hyperglycemia and hematologic disorders) hinder their utilization as a useful long-term adjuvant treatment. These systemic side effects and financial costs will reduce patient compliance and the value of antihormone therapy will be lost. It is difficult to maintain compliance for current antihormonal agents for 5 years, so an increase in side effects will result in the failure to control disease recurrence. We suggest another path in the final sections of this review.

Consideration for implementing a pathway forward that saves lives following a diagnosis of prostate and breast cancer
=====================================================================================================================

Enormous progress has occurred in the last 40 years in the approach to treating prostate and breast cancer. In the period 1967--1977 there were no proactive detection programs, diagnosis was usually late stage disease and the word cancer was not used. Quite rightly, cancer had the reputation as a death sentence. Radical surgery and radiotherapy were the major weapons in the physicians armamentarium and chemical therapy (chemotherapy) was primitive. Medical oncology was an emerging specialty. High-dose estrogen therapy was effective in 30% of both metastatic breast and prostate cancers, but this was a paradox as both breast and prostate cancers were known to be sex steroid dependent. Mechanisms were unknown.

A significant step forward occurred in breast cancer treatment with the publication of a symposium at King's College, Cambridge (28--29th September, 1977) in the October Supplement of Reviews in Endocrine-Related Cancer ([@bib128]), the fore-runner of the current Society for Endocrinology journal Endocrine-Related Cancer. The conclusions, which hold true today, were: (1) treating animals with a large tumor burden cannot affect a cure; (2) the tumor ER is important to predict a response to tamoxifen; (3) treating with tamoxifen early in tumorigenesis: i.e. low tumor burden, produces some protection for animals; (4) longer treatment with tamoxifen is superior to short treatment in animals with microscopic disease.

This and subsequent publications ([@bib128], [@bib143], [@bib147], [@bib141]) triggered the move to long-term adjuvant antiestrogen therapy proven to save lives ([@bib95], [@bib65]). As illustrated in this current review of prostate and breast cancer treatments, the diseases run different courses. Adjuvant therapy in prostate cancer is not implemented in the same way as is routine for breast cancer. In breast cancer, antihormone therapy is used to benefit patients in all stages of breast cancer, but the same is not true for prostate cancer. ADT is only used in MPC, locally advanced or recurring cases. Nevertheless, our review illustrates that the evolution of acquired resistance for both breast and prostate cancer is similar. Mechanisms of acquired resistance are broadly the same or the adaptions of alternate growth stimulating pathways are similar. The major risk factor for both prostate and breast cancer, is age. A primary consideration is to seek effective therapeutic solutions for our aging population. Resources are scarce and our goal of achieving chemoprevention of breast and prostate cancers has fallen short. We still do not know precisely who will develop breast or prostate cancer, and why. Treating large population to benefit a few, who do not know their disease was prevented, was an ineffective approach. Side effects from any chemopreventive intervention are unacceptable to any but the most committed high-risk woman who wishes to prevent breast cancer. A strategy to prevent prostate cancer using an inhibitor of 5α-reductase was scientifically sound ([@bib116], [@bib11], [@bib253]) but outcomes were controversial due to potential risks of high-grade prostate cancers and this advance in health care was abandoned ([@bib85], [@bib252]). The chemoprevention solution has overwhelmed healthcare systems. There is neither physician time to address individual needs for chemoprevention ([@bib242]) nor, it seems, physician knowledge about options ([@bib242]). We must, therefore, do what can be done to aid patients with breast and prostate cancers. This strategy must be inexpensive, globally applicable and aim to keep as many individuals well who can continue to contribute effectively to the welfare of the family. This essential goal will impact on the welfare of countries as each family unit can contribute to the economy of that country. In the final section we will address what can be done, how and why the approach is feasible.

An approach to global health care maintenance in prostate and breast cancers
============================================================================

Tamoxifen has taught us the fundamental laws of clinical therapeutics. To this day, antihormone therapy of MBC plus/minus chemotherapy or precision medicines (to block cell replication or the survival pathways that subvert antihormone action away from the ER growth pathway) can delay but not prevent death ([@bib1]). The same medicine tamoxifen or now an AI (letrozole) applied as a long-term adjuvant therapy, can delay recurrence and decrease mortality. Laboratory studies of acquired resistance to antihormone therapies ([@bib268], [@bib272], [@bib244]) opened the door to understanding the 'carry over' effect of long-term adjuvant antiestrogen therapy that decreases mortality after adjuvant therapy is stopped ([@bib88], [@bib61], [@bib205]).

The knowledge of mechanisms in adjuvant therapy in breast cancer can now be built upon to enhance survivorship and improve the quality of life during long-term adjuvant therapy. By contrast, the urologic community must decide whether select patients, destined to remain hormone responsive, could or should be treated with adjuvant ADT. An approach would be to correlate the genomics of indolent primary tumors with outcomes at recurrence that is antihormone responsive MPC. In this way, analysis of large data sets could save lives. The identification of those tumors that recur with MPC but subsequently respond to ADT would be candidates for adjuvant approaches in the future. Indeed, long drug holidays or androgen therapy may benefit patients with androgen-induced apoptosis of microscopic disease. Until that time, the strategy of long-term adjuvant control of prostate cancer cannot be considered.

For breast cancer, by contrast, the landscape holds numerous affordable possibilities. The AIs have reduced RR, with fewer serious side effects, but results of survivorship are less clear than with the SERM tamoxifen. However, the creation of the 'estrogen-free' woman for the remainder of her life, during adjuvant AI therapy, has concerns for general health. Osteoporosis is a concern, as is the less well-defined issues of coronary heart disease (CHD) and reduced mental capacity. This may include exacerbation of Alzheimer's disease for our aging population. Clearly, large populations of patients with Alzheimer's should be examined to determine whether breast cancer adjuvant treatment with either tamoxifen or AIs advance Alzheimer's onset or exacerbates symptoms and severity.

The 'SERMs Solution' ([@bib161]) for the chemoprevention of breast cancer now has a role to improve long-term adjuvant therapy. The original proposal for SERM was:

> 'Important clues have been garnered about the effects of tamoxifen on bone and lipids so it is possible that derivatives could find targeted applications to retard osteoporosis or atherosclerosis. The ubiquitous application of novel compounds to prevent diseases associated with the progressive changes after menopause may, as a side effect, significantly retard the development of breast cancer.' ([@bib161])

Following the success of the pioneering SERM tamoxifen, the medicinal chemistry community has advanced numerous safe and widely used new SERMs including raloxifene, bazedoxifene and ospemifene ([@bib174]). All are FDA approved for different indications in postmenopausal women's health. Only raloxifene has a cancer indication; the chemoprevention of breast cancer in high-risk postmenopausal women. Lasofoxifene is not yet approved but promises not only to reduce fracture risk in osteoporosis, reduce breast cancer incidence, and reduce strokes, but is the only SERM proven to reduce CHD ([@bib59]). Turning around the 'SERM solution' for women's health one more time, there is a strategic opportunity for medicinal chemists to solve one of the important molecular mechanisms of acquired AI resistance, i.e.: expansion and mutations of the ER. However, this must be achieved not with an orally active pure antiestrogen ([@bib1]), but a SERM that destroys the ER.

Orally active 'pure antiestrogens' are a current focus of medicinal chemistry with the goal of being effective therapies in MBC after the failure of AI therapy ([@bib1]). But this is not good enough. The oral pure antiestrogen solution as a future adjuvant therapy would still keep women estrogen free.

Medicinal chemists already know how to make a SERM that maintains bone density in ovarierectomized rats, but destroys the tumor cell ER ([@bib267], [@bib24]). The compound GW-5638 (Etacstil), was reported 20 years ago! The acrylic 'antiestrogenic' side chain when attached to the triphenyethylene core, fits appropriately into the ER ligand-binding domain but causes perturbation of the ER complex, resulting in rapid destruction ([@bib269]). This acrylic side chain is a recurrent feature of the 'new pure antiestrogens' under investigation ([@bib1]).

A new SERM that destroys tumor ER, used as an adjuvant therapy, would not only enhance survivorship by reducing recurrence noted with AIs, but also improve woman's health. Current problems of compliance can be addressed and improved. Women struggle with poor quality of life with AIs. Even a 3 month trial of local estrogen (or testosterone) is currently being evaluated to eliminate vaginal atrophy ([@bib176]), but a SERM could also achieve the same result ([@bib140]). Quality of life and being well is an essential component of patient survival. Stopping long-term adjuvant therapy prematurely, because of a lack of compliance, is the same as deciding upon a couple of years of adjuvant therapy. To stop adjuvant therapy early is not recommended. Indeed, the value of more than 5 years of adjuvant therapy has been evaluated. Ten years of adjuvant tamoxifen is superior to 5 years of adjuvant tamoxifen in lives saved, but only in the five years after completion of 10 years of adjuvant tamoxifen ([@bib65]). This is the essential role of estrogen-induced apoptosis, but the value in lives saved with an adjuvant AI is less clear ([@bib97]).

The Study of Letrozole Extension (SOLE) addressed the issue of 3 month drug holidays annually ([Fig. 6](#fig6){ref-type="fig"}) but now is an opportunity to advance a new adjuvant therapy strategy. The goal of the study was to establish that a woman's own estrogen would benefit patients by triggering estrogen-induced apoptosis. Invoking a physiologic antitumor mechanism would reduce micrometastatic disease and decrease recurrence. The hypothesis was based on published laboratory evidence ([@bib268], [@bib272], [@bib244]). Though recommended at the time, administration of low-dose estrogen was considered too dangerous for patients without clinical evidence of efficacy and safety. The clinical studies have now occurred ([@bib77], [@bib8]) so the laboratory concept is sound. The SOLE study is now reported ([@bib54]) but shows no benefit for intentional 3 month annual drug holidays for 4 consecutive years of letrozole adjuvant therapy. Nevertheless, the SOLE trial provides significant important new information for two further advances in women's health. Figure 6A schematic representation of the Study of Letrozole Extension (SOLE) trial. SOLE is a phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who had received 4--6 years of adjuvant endocrine therapy for hormone receptor (HR)- positive, lymph node- positive, early-stage breast cancer (BC). The rationale of SOLE trial was to test if 3-month treatment-free intervals during extended adjuvant endocrine therapy, would improve disease-free survival (DFS). The underpinning of this hypothesis is based on the theory that letrozole withdrawal for 3 months would allow a degree of estrogenic stimulation toward residual resistant disease, and subsequently the residual disease would become susceptible to letrozole reintroduction. The primary endpoint was DFS (randomization until invasive local, regional, distant recurrence or contralateral BC; 2nd malignancy; death). Postmenopausal women with prior 4--6 years of adjuvant endocrine therapy, were randomized into two arms: first arm is control which is continuous letrozole of 2.5 mg/daily for 5 years, and the second arm is intermittent letrozole of 2.5 mg/daily for 9 months in the first 1--4 years and fully at year 5. The trial concluded no difference in DFS among the two arms but for the first time pre-planned medication non-adherence is not harmful. This can provide a treatment-side effects and financial relief to many patients.

Our goal here is to propose a long-term therapeutic strategy that not only builds on past clinical experience, but also introduces a new strategic concept for adjuvant therapy to improve patient care globally. The new information from the SOLE trial is a first step forward. Firstly, the fact that a patient can stop therapy for 3 months and then restart adjuvant therapy allows compliance issues, due to side effects, to be addressed. A vigilant breast team can now offer returning to continuous adjuvant AI therapy to patients in distress. Secondly, the 3 month adjuvant window can now be used to create an advance in adjuvant therapy to reduce the micrometastatic tumor burden for those patients known to be at high risk for recurrence and death if a second five years of adjuvant therapy is not enforced ([@bib2]). This is important, as a short-term intensive preemptive salvage therapy ([Fig. 7](#fig7){ref-type="fig"}), because cost and toxic side effects for current precision medicines (palbociclib and everolimus) will make years of combination therapy with an innovative antiestrogen therapy impractical ([@bib44]). But how should the clinical community advance the new therapeutic innovations? Figure 7A schematic representation of the proposed design (alongside a proposed optimized version) for the preemptive salvage therapy. (A) Breast cancer patients who are ER- positive after surgery and at high risk of recurrence (this includes large primary tumors and positive lymph nodes at diagnosis), can harness the benefits of long-term estrogen deprivation, with a preemptive salvage therapy, aiming at clearing occult micrometastases. After 5 years of adjuvant antihormonal therapy with either tamoxifen or AIs, breast cancer cell populations undergo selection pressure. The new long-term estrogen-deprived (LTED) breast cancer cell populations are now vulnerable to a woman's own estrogen through apoptosis (aka estrogen-independent). Whereas, they would normally grow with estrogen within 5 years past menopause (aka estrogen-dependent). The clinically observed response rate to low-dose estrogen therapy was 30% in metastatic breast cancer. Estrogen can act in synergy with other FDA approved breast cancer cell survival inhibitors or apoptosis promoters. This synergy can potentially increase the response rate above 30%. (B) Panel A can be optimized. Estrogen deprivation can be achieved with a new SERM that degrades the ER, preventing future drug resistance and receptor mutations. As one example, there is an orally active SERD, GW5638, which is metabolically hydroxylated to GW7604, in the same way, tamoxifen is metabolically activated to 4-hydroxytamoxifen. Unlike tamoxifen, GW7608 triggers the destruction of ER in BC cells, while retaining an estrogenic tickle at ER elsewhere (i.e. bones and serum lipids). Although GW7608 is a SERD for degrading the ER, it is also a SERM due to its agonistic and antagonistic mechanism of action at different tissue levels. A similar mechanistic SERM/SERD compound can improve estrogen deprivation (with an AI) by destroying the ER, while maintaining women's health. In addition, estrogen in the proposed 3-month drug holiday can be replaced with selective human estrogen receptor partial agonist (ShERPA). These compounds mimic estrogen without causing significant uterine growth and were found to inhibit the growth of endocrine-independent tamoxifen-resistant breast cancer cell lines.

Firstly, there has to be clearly defined patient population that is at high risk of recurrence despite long-term adjuvant antihormone therapy. Recent data reported by the Early Breast Cancer Trialists Collaborative Group (EBCTCG) ([@bib193]) define that high-risk population that recurs following 5 years of adjuvant tamoxifen. Follow-up is for 15 years and, not surprisingly, RR depend upon the size of the original primary tumor and the number of axillary lymph nodes. Secondly, there needs to be a defined combination of physiologic estrogen plus a cocktail of precision medicines to reduce the burden of micrometastatic disease and avoid recurrence ([@bib144]). The goal is to kill micrometastatic disease not just hold cancer cell growth. Understandable concerns are raised still about the safety of low-dose estrogen ([@bib213]) and this is appropriate, but medicinal chemists are already addressing the problem. Raloxifene derivatives that trigger apoptosis in LTED breast cancer, have been reported ([@bib270]) and clinical trials are planned.

Secondly, studies using FDA approved low-dose estrogen (FDA approved!) and cocktails of precision survival inhibitors in LTED breast cancer can be confirmed to be effective in LTED MBC. The strategy would be in place for the evaluation of the best selective human estrogen receptor partial agonist (ShERPA) ([@bib270]) to then go into the adjuvant testing. Already liquid biopsies for breast cancer with low tumor burden are being advanced in clinical testing ([@bib203]). This technical advance will support adjuvant monitoring of apoptotic success.

Breast cancer treatment must evolve to improve women's health. The view that 'this is good enough' must not take hold. A new SERM for adjuvant therapy must be the best to improve women's health and the best to prevent breast cancer recurrences. Knowledge now exists for the eventual implementation of a new preemptive salvage therapy ([Fig. 7](#fig7){ref-type="fig"}) strategies based on the planned drug holidays in SOLE, and the use of a new SERM with a positive health pharmacology to replace AIs. Together, a new adjuvant SERM that destroys the ER with a SOLE adjuvant design of 3 month therapeutic windows, using precision medicines that kill micrometastatic breast cancer, would be an optimal strategy for breast cancer therapy to achieve. This would be cheap once patenting of precision medicines lapses, easy to administer orally and would address all current issues with current AI therapy. Nevertheless, it will be said that the plan could take decades so it cannot (should not) be attempted.

Forty years ago ([@bib128]), there was no long-term adjuvant therapy, no understanding of dangerous side effects with tamoxifen, i.e. endometrial cancer, no AIs or SERMs for women's health. The strategy of long-term adjuvant therapy in breast cancer was considered 'mindless' ([@bib246]) at best and would not improve patient care, and dangerous at worst as it would encourage premature drug resistance. These medical opinions did not go unchallenged ([@bib130]). Instead, the translational adjuvant strategies using antiestrogens conceived in the laboratory in the 1970/80s, gave patients fewer RR, unanticipated major decreases in mortality, fewer contralateral breast cancers, awareness of the link between tamoxifen and endometrial cancer, an understanding of the unique mechanisms of acquired resistance to antihormones that can be used to treat breast and prostate cancer and the new science of sex steroid-induced apoptosis. It is now prudent to plan for improvements in clinical care and build on past clinical advances.
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This article is submitted to celebrate Dr Jordan's 70th birthday, the 40th anniversary of his proposal to use long-term adjuvant tamoxifen therapy clinically, and his discovery of the new group of medicines called SERMs, with tamoxifen as the pioneering SERM. His body of research work is recognized by the Endocrine Society with Dr Jordan's selection as the 2018 Endocrine Society Laureate of the Gerald D Aurbach Award for Outstanding Translational Research.

[^1]: They have been categorized by their dependence on the hormone receptors or hormones themselves.
